QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
NASDAQ:APLS

Apellis Pharmaceuticals - APLS Stock Forecast, Price & News

$60.49
-0.55 (-0.90%)
(As of 10/4/2022 12:00 AM ET)
Add
Compare
Today's Range
$59.66
$63.22
50-Day Range
$55.67
$68.67
52-Week Range
$30.17
$70.00
Volume
2.45 million shs
Average Volume
1.19 million shs
Market Capitalization
$6.65 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$76.23

Apellis Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.77 Rating Score
Upside/​Downside
26.0% Upside
$76.23 Price Target
Short Interest
Bearish
8.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.62
Upright™ Environmental Score
News Sentiment
0.67mentions of Apellis Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$7.15 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.92) to ($4.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

503rd out of 1,087 stocks

Pharmaceutical Preparations Industry

233rd out of 546 stocks

APLS stock logo

About Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

APLS Stock News Headlines

Small-Cap Catalyst Pharma Is Among Market's Best Price Performers (APLS)
Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.
Apellis Pharmaceuticals Inc - Stock Chart
See More Headlines
Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

APLS Company Calendar

Last Earnings
8/08/2022
Today
10/04/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APLS
Fax
N/A
Employees
476
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$76.23
High Stock Price Forecast
$113.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+26.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.77
Research Coverage
13 Analysts

Profitability

Net Income
$-746,350,000.00
Net Margins
-660.59%
Pretax Margin
-658.47%

Debt

Sales & Book Value

Annual Sales
$66.56 million
Book Value
$2.04 per share

Miscellaneous

Free Float
101,076,000
Market Cap
$6.65 billion
Optionable
Not Optionable
Beta
1.36

Key Executives

  • Dr. Cedric Francois M.D.Dr. Cedric Francois M.D. (Age 50)
    Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $969.54k
  • Dr. Pascal Deschatelets Ph.D.Dr. Pascal Deschatelets Ph.D. (Age 52)
    Co-Founder & Chief Scientific Officer
    Comp: $609.85k
  • Dr. Federico Grossi M.D.Dr. Federico Grossi M.D. (Age 48)
    Ph.D., Co-Founder & Chief Medical Officer
    Comp: $578.01k
  • Mr. Alec Machiels J.D.Mr. Alec Machiels J.D. (Age 49)
    MBA, Co-Founder & Director
    Comp: $72.5k
  • Mr. Timothy E. Sullivan (Age 51)
    CFO & Treasurer
    Comp: $630.17k
  • Mr. Adam J. TownsendMr. Adam J. Townsend (Age 45)
    Chief Commercial Officer
    Comp: $602.69k
  • Ms. Nur Nicholson
    Chief Technical Operations Officer
  • Mr. James G. Chopas CPA (Age 56)
    VP, Corp. Controller & Chief Accounting Officer
  • Ms. Meredith Kaya
    Sr. VP, Investor Relations & Strategic Fin.
  • Mr. David O. WatsonMr. David O. Watson (Age 49)
    Gen. Counsel













APLS Stock - Frequently Asked Questions

Should I buy or sell Apellis Pharmaceuticals stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APLS shares.
View APLS analyst ratings
or view top-rated stocks.

What is Apellis Pharmaceuticals' stock price forecast for 2022?

13 analysts have issued 1 year price targets for Apellis Pharmaceuticals' stock. Their APLS share price forecasts range from $40.00 to $113.00. On average, they predict the company's share price to reach $76.23 in the next year. This suggests a possible upside of 26.5% from the stock's current price.
View analysts price targets for APLS
or view top-rated stocks among Wall Street analysts.

How have APLS shares performed in 2022?

Apellis Pharmaceuticals' stock was trading at $47.28 at the start of the year. Since then, APLS shares have increased by 27.5% and is now trading at $60.26.
View the best growth stocks for 2022 here
.

When is Apellis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our APLS earnings forecast
.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) issued its earnings results on Monday, August, 8th. The company reported ($1.46) EPS for the quarter, missing the consensus estimate of ($1.43) by $0.03. The firm earned $16.32 million during the quarter, compared to the consensus estimate of $17.16 million. Apellis Pharmaceuticals had a negative net margin of 660.59% and a negative trailing twelve-month return on equity of 272.25%. During the same period in the previous year, the business posted ($2.72) EPS.

What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $60.26.

How much money does Apellis Pharmaceuticals make?

Apellis Pharmaceuticals (NASDAQ:APLS) has a market capitalization of $6.62 billion and generates $66.56 million in revenue each year. The company earns $-746,350,000.00 in net income (profit) each year or ($6.77) on an earnings per share basis.

How many employees does Apellis Pharmaceuticals have?

The company employs 476 workers across the globe.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The official website for the company is www.apellis.com. The company can be reached via phone at (617) 977-5700 or via email at investors@apellis.com.

This page (NASDAQ:APLS) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.